via Perelman School of Medicine
Promising results in animal models help pave the way for clinical trials
An experimental mRNA-based vaccine against all 20 known subtypes of influenza virus provided broad protection from otherwise lethal flu strains in initial tests, and thus might serve one day as a general preventative measure against future flu pandemics, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.
The “multivalent” vaccine, which the researchers describe in a paper published today in Science, uses the same messenger ribonucleic acid (mRNA) technology employed in the Pfizer and Moderna SARS-CoV-2 vaccines. This mRNA technology that enabled those COVID-19 vaccines was pioneered at Penn. Tests in animal models showed that the vaccine dramatically reduced signs of illness and protected from death, even when the animals were exposed to flu strains different from those used in making the vaccine.
“The idea here is to have a vaccine that will give people a baseline level of immune memory to diverse flu strains, so that there will be far less disease and death when the next flu pandemic occurs,” said study senior author Scott Hensley, PhD, a professor in of Microbiology at in the Perelman School of Medicine.
Hensley and his laboratory collaborated in the study with the laboratory of mRNA vaccine pioneer Drew Weissman, MD, PhD, the Roberts Family Professor in Vaccine Research and Director of Vaccine Research at Penn Medicine.
Influenza viruses periodically cause pandemics with enormous death tolls. The best known of these was the 1918-19 “Spanish flu” pandemic, which killed at least tens of millions of people worldwide. Flu viruses can circulate in birds, pigs, and other animals, and pandemics can start when one of these strains jumps to humans and acquires mutations that adapt it better for spreading among humans. Current flu vaccines are merely “seasonal” vaccines that protect against recently circulating strains, but would not be expected to protect against new, pandemic strains.
The strategy employed by the Penn Medicine researchers is to vaccinate using immunogens—a type of antigen that stimulates immune responses—from all known influenza subtypes in order to elicit broad protection. The vaccine is not expected to provide “sterilizing” immunity that completely prevents viral infections. Instead, the new study shows that the vaccine elicits a memory immune response that can be quickly recalled and adapted to new pandemic viral strains, significantly reducing severe illness and death from infections.
“It would be comparable to first-generation SARS-CoV-2 mRNA vaccines, which were targeted to the original Wuhan strain of the coronavirus,” Hensley said. “Against later variants such as Omicron, these original vaccines did not fully block viral infections, but they continue to provide durable protection against severe disease and death.”
The experimental vaccine, when injected and taken up by the cells of recipients, starts producing copies of a key flu virus protein, the hemagglutinin protein, for all twenty influenza hemagglutinin subtypes—H1 through H18 for influenza A viruses, and two more for influenza B viruses.
“For a conventional vaccine, immunizing against all these subtypes would be a major challenge, but with mRNA technology it’s relatively easy,” Hensley said.
In mice, the mRNA vaccine elicited high levels of antibodies, which stayed elevated for at least four months, and reacted strongly to all 20 flu subtypes. Moreover, the vaccine seemed relatively unaffected by prior influenza virus exposures, which can skew immune responses to conventional influenza vaccines. The researchers observed that the antibody response in the mice was strong and broad whether or not the animals had been exposed to flu virus before.
Hensley and his colleagues currently are designing human clinical trials, he said. The researchers envision that, if those trials are successful, the vaccine may be useful for eliciting long-term immune memory against all influenza subtypes in people of all age groups, including young children.
“We think this vaccine could significantly reduce the chances of ever getting a severe flu infection,” Hensley said.
In principle, he added, the same multivalent mRNA strategy can be used for other viruses with pandemic potential, including coronaviruses.
Original Article: Penn Scientists develop 20-subtype mRNA flu vaccine to protect against future flu pandemics
More from: Perelman School of Medicine at the University of Pennsylvania
The Latest Updates from Bing News
Go deeper with Bing News on:
Multivalent vaccine
- New mRNA Vaccines in Development for Cancer and Infections
Prelog also discussed personalized vaccines for cancer immunotherapy. Personalized mRNA vaccines are tailored to the patient's genetic characteristics and antigens. They could be used in cancer ...
- Promising Outlook As Biotech Sector Advances Cancer Treatments Amidst Rising Diagnoses
Yum Brands Misses Estimates CVS Tumbles on Q1 Figures Securing America's Future: New Investments Aim to Reduce Dependency on Im ...
- Senior official says efforts still needed to improve immunization program
While acknowledging the critical role of the national immunization program in controlling infectious diseases, Li called attention to challenges in sustaining the country's polio-free status, ...
- Global leaders highlight need to defeat meningitis at WHO and France meeting
April 2024 at the Institut Pasteur and is supported by prominent athletes advocating on the cause ahead of the Paris Paralympics.
- Vaccines News
Mar. 12, 2024 — Researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to ... Mar. 8, 2024 — COVID ...
Go deeper with Bing News on:
mRNA flu vaccine
- Launching an effective bird flu vaccine quickly could be tough, scientists warn
Federal health officials say the U.S. has the building blocks to make a vaccine to protect humans from bird flu, if needed. But experts warn we're nowhere near prepared for another pandemic.
- Moderna (MRNA) Q1 2024 Earnings Call Transcript
Welcome to the Moderna's first-quarter 2024 conference call. [Operator instructions] Please be advised, today's conference is being recorded. I would now like to hand the conference over to your ...
- New mRNA Vaccines in Development for Cancer and Infections
Prelog also discussed personalized vaccines for cancer immunotherapy. Personalized mRNA vaccines are tailored to the patient's genetic characteristics and antigens. They could be used in cancer ...
- Vaccine Developers Leverage mRNA and Other Powerful Technologies
In addition to influenza, Osivax is developing vaccines for Sarbecovirus and human papillomavirus, and is cultivating an mRNA vaccine program. Clinical virologist and biopharma executive and ...
- Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Moderna MRNA will report first-quarter 2024 results on May 2, before the opening bell. In the last reported quarter, the company reported an earnings surprise of 170.51%. Factors to Note The Zacks ...